What is Chimeric Therapeutics?
Founded in 2020 and headquartered in Carlton, Australia, Chimeric Therapeutics is a biotechnology firm dedicated to the research and development of cutting-edge cancer therapies. The company's core mission involves progressing its portfolio of novel therapeutic solutions through rigorous clinical trials and scientific investigation to address critical unmet needs within the oncology landscape. Operating within the business services and research and development sectors, Chimeric Therapeutics actively collaborates with healthcare institutions to further its development of advanced cancer treatment modalities.
How much funding has Chimeric Therapeutics raised?
Chimeric Therapeutics has raised a total of $53.5M across 3 funding rounds:
Stock Offering
$35M
Share Placement
$10.1M
Stock/Share Issuance
$8.4M
Stock Issuance/Offering (2021): $35M, investors not publicly disclosed
Share Placement (2023): $10.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $8.4M, investors not publicly disclosed
What's next for Chimeric Therapeutics?
The recent major strategic investment positions Chimeric Therapeutics for accelerated growth and the advancement of its clinical programs. This capital infusion is expected to fuel further research and development, potentially enabling the company to expand its therapeutic pipeline and move promising candidates closer to market. The company's focus on innovative oncology solutions suggests a strategic direction aimed at capturing significant market share in a rapidly evolving healthcare sector. Future developments will likely center on clinical trial outcomes and strategic partnerships to enhance its therapeutic offerings.
See full Chimeric Therapeutics company page
